Detail

Study ID: Merck MK-6482-013

Title:

Phase 2 study of MK-6482 in participants with advanced renal cell carcinoma.

Location:
Sioux Falls Region
Principal Investigator:
Christopher Sumey, MD
Disease:
REN (Renal)
Stage:
Phase II
Status:
Active - Open to Accrual